<DOC>
	<DOCNO>NCT00151879</DOCNO>
	<brief_summary>Subjects enrol SP615 , SP756 , SP774 open-label extension ( OLE ) trial receive oral SPM 927 least 8 week stable dose 3 antiepileptic medication may participate research trial approximately 30 location . Trial objective include investigate whether iv SPM 927 safe well tolerate give twice daily short period time identify appropriate infusion rate ( ) . Subjects receive SPM 927 30- , 15- 10- minute infusion twice daily 2 - 5 day base notification research doctor subject choice . Subjects remain stable dose receive OLE trial . Trial procedure include medical history update , physical/ neurological exam , ECGs , blood /urine sample collection seizure diary completion . Subjects complete trial return OLE trial resume dose oral SPM 927 .</brief_summary>
	<brief_title>Safety Tolerability Intravenous SPM 927 Replacement Oral SPM 927 Subjects With Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<criteria>Partial seizure without secondary generalization . Subject previously receive iv lacosamide . Subject meet withdrawal criterion openlabel extension trial .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>partial seizure without secondary generalization</keyword>
</DOC>